Sale!

Erythropoietin Protein (Human EPO)

$675.00 $495.00

Catalog #: P2010011 (25 ug)

Erythropoietin Protein (EPO) is glycoprotein belonging to the cytokines type I family and produced primarily by the kidneys. EPO plays a major in the regulation of red blood cells production. Applications of this product include ELISA and SDS-PAGE. For research use only.

ATTENTION: This product is for Research Use Only. This product is NOT for human or veterinary use. This product is for academic or biotech research laboratories only.

Live Enquiry about this product via Text/SMS: 1-858-900-3210 (8 am – 8 pm PST)

In stock

SKU: P2010011 Category:

Description

Human Erythropoietin Protein (EPO)

Product Data Sheet Download Data Sheet
MSDS Download MSDS
Catalog number: P2010011
Lot number: 0119P0011
Expiration date: 4/7/23
Package Size: 25 ug
Synonyms: MVCD2 protein, EPO protein, EP protein
Source: Recombinant (insect cells)
Molecular Weight: 20 kDa
Concentration: 250 μg/mL
Buffer: PBS + 10% Glycerol
Storage: -20°C or lower. Avoid repeated freeze-thaw.

 

References

  • Erythropoietin Does Not Alter Serum Profiles of Neuronal and Axonal Biomarkers After Traumatic Brain Injury: Findings From the Australian EPO-TBI Clinical Trial.  Hellewell SC, Mondello S, Conquest A, Shaw G, Madorsky I, Deng JV, Little L, Kobeissy F, Bye N, Bellomo R, Cooper DJ, Vallance S, Board J, Morganti-Kossmann MC. Crit Care Med. 2018 Apr;46(4):554-561.
  • Roxadustat (FG-4592) Versus EpoetinAlfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, Poole L, Saikali KG, Saha G, Hemmerich S, Szczech L, Yu KH, Neff TB. Am J Kidney Dis. 2016 Jun;67(6):912-24.
  • A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. Fenaux P, Santini V, Spiriti MAA, Giagounidis A, Schlag R, Radinoff A, Gercheva-Kyuchukova L, Anagnostopoulos A, Oliva EN, Symeonidis A, Berger MH, Götze KS, Potamianou A, Haralampiev H, Wapenaar R, Milionis I, Platzbecker U. Leukemia. 2018 Dec;32(12):2648-2658.
  • Structure-Function Relationships for Recombinant Erythropoietins: A Case Study From a Proposed Manufacturing Change With Implications for Erythropoietin Biosimilar Study Designs. Grampp G, McElroy PL, Camblin G, Pollock A. J Pharm Sci. 2018 Jun;107(6):1512-1520.
  • Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients. Azmandian J, Abbasi MR, Pourfarziani V, Nasiri AA, Ossareh S, Ezzatzadegan Jahromi S, Sanadgol H, Amini S, Shahvaroughi Farahani A. Am J Nephrol. 2018;48(4):251-259.